Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.

NCT01839188 is registered in ClinicalTrials.gov with MCM Vaccines B.V. as lead sponsor.

NCT NCT01839188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01839188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.
Lead sponsor
MCM Vaccines B.V.
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2013
Completion date
March 19, 2014
Enrollment
385 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections, neisseria meningitidis, virus diseases